Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LMNL Stock Summary
In the News
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
Liminal BioSciences to Present at BIO CEO & Investor Conference
LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
Liminal Biosciences to Present at Upcoming Investor Conferences
LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.
LMNL Financial details
LMNL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 572.15 | 3.05 | 1.36 | 0.21 | 0.13 | |
Net income per share | -2.36K | -145.82 | -49.97 | -14.94 | -9.32 | |
Operating cash flow per share | -995.82 | -61.88 | -31.06 | -33.02 | -10.25 | |
Free cash flow per share | -1.06K | -64.65 | -31.9 | -33.18 | -10.26 | |
Cash per share | 89.24 | 38.16 | 18.44 | 35.97 | 11.97 | |
Book value per share | -683.62 | 63.62 | 9.45 | 14.14 | 11.66 | |
Tangible book value per share | -1K | 50.48 | -0.2 | 10.07 | 10.62 | |
Share holders equity per share | -683.62 | 63.62 | 9.45 | 14.14 | 11.66 | |
Interest debt per share | 1.88K | 38.06 | 33.84 | 22.25 | 0.83 | |
Market cap | 219.94M | 175.8M | 130.88M | 41.9M | 13.66M | |
Enterprise value | 346.05M | 161.58M | 159.79M | -5.81M | -22M | |
P/E ratio | -1.13 | -0.75 | -1.07 | -0.93 | -0.47 | |
Price to sales ratio | 4.64 | 35.85 | 39.46 | 65.16 | 34.06 | |
POCF ratio | -2.67 | -1.77 | -1.72 | -0.42 | -0.43 | |
PFCF ratio | -2.51 | -1.69 | -1.68 | -0.42 | -0.43 | |
P/B Ratio | -3.89 | 1.72 | 5.67 | 0.98 | 0.38 | |
PTB ratio | -3.89 | 1.72 | 5.67 | 0.98 | 0.38 | |
EV to sales | 7.3 | 32.95 | 48.17 | -9.04 | -54.86 | |
Enterprise value over EBITDA | -3.2 | -0.8 | -1.86 | 0.13 | 0.69 | |
EV to operating cash flow | -4.2 | -1.63 | -2.1 | 0.06 | 0.69 | |
EV to free cash flow | -3.95 | -1.56 | -2.05 | 0.06 | 0.69 | |
Earnings yield | -0.89 | -1.33 | -0.93 | -1.08 | -2.12 | |
Free cash flow yield | -0.4 | -0.59 | -0.6 | -2.39 | -2.33 | |
Debt to equity | -2.36 | 0.46 | 3.2 | 1.43 | 0.04 | |
Debt to assets | 1.3 | 0.29 | 0.63 | 0.48 | 0.03 | |
Net debt to EBITDA | -1.17 | 0.07 | -0.34 | 1.06 | 1.12 | |
Current ratio | 1.14 | 3.03 | 3.07 | 6.2 | 4.09 | |
Interest coverage | -5.08 | -14.99 | -10.81 | -7.83 | -30.59 | |
Income quality | 0.35 | 0.48 | 0.64 | -8.16 | -51.16 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 1.93 | 15.32 | 17.13 | 28.53 | 38.15 | |
Intangibles to total assets | 0.19 | 0.08 | 0.13 | 0.03 | 0.06 | |
Capex to operating cash flow | 0.06 | 0.04 | 0.03 | 0 | 0 | |
Capex to revenue | -0.11 | -0.91 | -0.62 | -0.72 | -0.05 | |
Capex to depreciation | -0.94 | -0.45 | -0.24 | -0.11 | -0.02 | |
Stock based compensation to revenue | 0.14 | 4.41 | 1.87 | 6.58 | 4.65 | |
Graham number | 6.02K | 456.89 | 103.09 | 68.94 | 49.45 | |
ROIC | -1.24 | -1.12 | -0.72 | -0.39 | -0.83 | |
Return on tangible assets | -2.35 | -1.55 | -1.19 | -0.37 | -0.61 | |
Graham Net | -1.66K | 3.03 | -20.49 | 5.68 | 7.66 | |
Working capital | 5.11M | 63.59M | 49.24M | 96.14M | 31.22M | |
Tangible asset value | -82.95M | 81.09M | -480K | 30.37M | 32.97M | |
Net current asset value | -125.2M | 24.69M | -29.75M | 22.46M | 27.07M | |
Invested capital | -2.36 | 0.46 | 3.2 | 1.43 | 0.04 | |
Average receivables | 15.46M | 16.64M | 8.6M | 2.49M | 1.12M | |
Average payables | 20.22M | 15.8M | 9.82M | 7.46M | 4.58M | |
Average inventory | 24.02M | 9.78M | 8.45M | 4.69M | 0 | |
Days sales outstanding | 153.88 | 989.91 | 429.48 | 606.25 | 1.07K | |
Days payables outstanding | 202.63 | 1.39K | 1.64K | 0 | 0 | |
Days of inventory on hand | 115.53 | 995 | 1.68K | 0 | 0 | |
Receivables turnover | 2.37 | 0.37 | 0.85 | 0.6 | 0.34 | |
Payables turnover | 1.8 | 0.26 | 0.22 | 0 | 0 | |
Inventory turnover | 3.16 | 0.37 | 0.22 | 0 | 0 | |
ROE | 3.45 | -2.29 | -5.29 | -1.06 | -0.8 | |
Capex per share | -61.93 | -2.77 | -0.84 | -0.15 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0 | 0.08 | 0.04 | 0.04 | |
Net income per share | -1.01 | 7.06 | -1.54 | -2.46 | -2.94 | |
Operating cash flow per share | -2.18 | -3.77 | -2.03 | -3.33 | -2.51 | |
Free cash flow per share | -2.19 | -3.77 | -2.02 | -3.33 | -2.51 | |
Cash per share | 17.98 | 13.13 | 11.97 | 8.68 | 6.22 | |
Book value per share | 8.78 | 13.02 | 11.67 | 9.36 | 6.92 | |
Tangible book value per share | 5.69 | 13.02 | 10.62 | 9.36 | 6.92 | |
Share holders equity per share | 8.78 | 13.02 | 11.67 | 9.36 | 6.92 | |
Interest debt per share | 7.73 | 0.81 | 0.42 | 0.51 | 0.39 | |
Market cap | 20.51M | 17.83M | 13.65M | 11.8M | 25.93M | |
Enterprise value | -12.17M | -21.36M | -22M | -13.79M | 7.82M | |
P/E ratio | -1.64 | 0.2 | -0.72 | -0.39 | -0.71 | |
Price to sales ratio | 130.67 | 5.94K | 56.65 | 86.73 | 231.48 | |
POCF ratio | -3.03 | -1.52 | -2.17 | -1.14 | -3.33 | |
PFCF ratio | -3.02 | -1.52 | -2.17 | -1.14 | -3.33 | |
P/B Ratio | 0.75 | 0.44 | 0.38 | 0.41 | 1.21 | |
PTB ratio | 0.75 | 0.44 | 0.38 | 0.41 | 1.21 | |
EV to sales | -77.54 | -7.12K | -91.3 | -101.4 | 69.83 | |
Enterprise value over EBITDA | 1.49 | 2.12 | 3.1 | 1.94 | -0.88 | |
EV to operating cash flow | 1.8 | 1.83 | 3.49 | 1.33 | -1.01 | |
EV to free cash flow | 1.79 | 1.83 | 3.5 | 1.33 | -1.01 | |
Earnings yield | -0.15 | 1.23 | -0.35 | -0.65 | -0.35 | |
Free cash flow yield | -0.33 | -0.66 | -0.46 | -0.88 | -0.3 | |
Debt to equity | 0.85 | 0.04 | 0.04 | 0.05 | 0.06 | |
Debt to assets | 0.33 | 0.03 | 0.03 | 0.03 | 0.04 | |
Net debt to EBITDA | 4.01 | 3.89 | 5.03 | 3.6 | 2.04 | |
Current ratio | 2.35 | 4.85 | 4.09 | 3.75 | 2.78 | |
Interest coverage | -9.71 | -10.82 | 38.4 | -34.1 | 0 | |
Income quality | 1.09 | -0.53 | 1.48 | 1.39 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 29.6 | 1.46K | 37.48 | 26.17 | 42.64 | |
Research and developement to revenue | 25.11 | 1.17K | 14.37 | 30.65 | 38.74 | |
Intangibles to total assets | 0.05 | 0.06 | 0.06 | 0.08 | 0.14 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.05 | -1 | 0.08 | 0 | 0 | |
Capex to depreciation | -0.03 | -0.01 | 0.07 | 0 | 0 | |
Stock based compensation to revenue | 3.42 | 137.67 | 1.22 | 2.11 | 2.17 | |
Graham number | 14.11 | 45.47 | 20.09 | 22.78 | 21.41 | |
ROIC | -0.06 | 1.52 | -0.13 | -0.23 | -0.38 | |
Return on tangible assets | -0.05 | 0.43 | -0.1 | -0.21 | -0.33 | |
Graham Net | 1.19 | 9.14 | 7.66 | 5.67 | 3.09 | |
Working capital | 35M | 35.18M | 31.22M | 25.05M | 16.4M | |
Tangible asset value | 14.27M | 37.1M | 32.97M | 25.89M | 17.06M | |
Net current asset value | 7.77M | 30.82M | 27.07M | 24.06M | 15.32M | |
Invested capital | 0.85 | 0.04 | 0.04 | 0.05 | 0.06 | |
Average receivables | 1.14M | 1.49M | 1.34M | 1.1M | 909K | |
Average payables | 4.05M | 0 | 1.7M | 1.7M | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 848.41 | 44.94K | 439.54 | 681.62 | 633.21 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.11 | 0 | 0.2 | 0.13 | 0.14 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | 0.54 | -0.13 | -0.26 | -0.43 | |
Capex per share | 0 | 0 | 0.01 | 0 | 0 |
LMNL Frequently Asked Questions
What is Liminal BioSciences Inc. stock symbol ?
Liminal BioSciences Inc. is a CA stock , located in Laval of Qc and trading under the symbol LMNL
What is Liminal BioSciences Inc. stock quote today ?
Liminal BioSciences Inc. stock price is $- today.
Is Liminal BioSciences Inc. stock public?
Yes, Liminal BioSciences Inc. is a publicly traded company.